Vardena®l, a novel selective phosphodiesterase type 5 inhibitor, was evaluated in its ®rst largescale at-home trial. A total of 601 men with mild to severe erectile dysfunction (ED) were enrolled in this multi-centre, randomized, double-blind, placebo-controlled trial of 12 weeks of treatment with either placebo or 5, 10 and 20 mg of vardena®l. Primary endpoints were Q3 (vaginal penetration) and Q4 (maintenance of erection) of the International Index of Erectile Function (IIEF). In the intent-to-treat population (n 580), the changes from baseline for 5, 10 and 20 mg vardena®l (1.2, 1.3 and 1.5, respectively) were all improved (P`0.001) over placebo (0.2) for Q3 and were similarly improved for Q4 (1.4, 1.5 and 1.7) compared to placebo (0.5) (P`0.001). All vardena®l doses improved all IIEF domains compared to placebo (P`0.001). The percentage of successful intercourses was between 71 and 75% for the three vardena®l doses. For the 20 mg dose, 80% of the patients experienced improved erections (GAQ) compared to 30% for placebo. Most frequent treatment-emergent adverse events were headache (7 ± 15%),¯ushing (10 ± 11%) and up to 7% for dyspepsia or rhinitis. Vardena®l treatment resulted in a high ef®cacy and low adverseevent pro®le in a population with mixed ED etiologies.
Introduction
Male erectile dysfunction (ED) represents a worldwide, multi-cultural condition with prevalence rates between 19 and 74% in the age groups 40 ± 80 y if all serverity categories from mild to severe are considered. 1 ± 6 Since ED is an apparently age-related phenomenon and the life-expectancy of the worldwide population is increasing, many couples are confronted with this condition as they get older. The negative impact of ED on the quality of life is documented in several studies. 7 ± 9 While self-injection therapy and penile implants will still have their place for a limited number of patients, 10 ,11 the management of male impotence was revolutionized after the introduction of oral sildena®l for both psychogenic and organic ED. Oral agents like yohimbine with questionable ef®cacy cannot be regarded as standard therapy, especially for organic ED. 12 Basic research into ED has demonstrated the importance of the nitric oxideaguanylyl cyclaseacyclic guanosine monophosphateaphosphodiesterase-5 (NOacGMPaPDE5) interactions for the natural erection process. 13 ± 17 Selective PDE5 inhibition with sildena®l has resulted in marked clinical ef®cacy in mixed ED patient groups. 18 ± 23 This PDE5 inhibition with subsequent cGMP accumulation has made this mechanism an attractive approach for the relief of erectile disorders and great efforts to optimise both the ef®cacy and the adverse event pro®le in this new therapeutic concept are underway world-wide. Vardena®l hydrochloride, a novel PDE5 inhibitor has shown the higher selectivity for PDE5 with an IC 50 of 0.7 nM. 24, 30 In comparison to the IC 50 of sildena®l in the same enzyme preparation, vardena®l was more potent indicating that lower drug doses will provide the same clinical ef®cacy, which has been proven at least for the conscious animal rabbit model. 24 Vardena®l is rapidly absorbed with a mean t max of 0.7 h and a terminal half-life (t 1a2 ) of more than 4 h. 25, 26 In two separate Rigiscan studies, vardena®l in doses of 10, 20 and 40 mg signi®cantly increased the quality and duration of erections in men with mixed ED as compared to placebo (P`0.001). 25, 26 The promising results of the phase I and IIa trials provided the basis for evaluating both the ef®cacy and safety of this novel PDE5 inhibitor in the ®rst athome use study in a large number of patients in order to investigate which doses will result in statistically signi®cant improvement in clinically meaningful outcomes.
Methods

Study design and patient population
This was an at-home, phase IIb, randomized, double-blind, placebo-controlled, multi-center, parallel-group dose-®nding study of males with ED. Eligible patients had a 4 week run-in period during which they attempted intercourse at least four times. Patients were then randomized to placebo tablets or 5 mg, 10 mg or 20 mg oral tablets (encased in capsules for blinding purposes) of vardena®l hydrochloride (Bayer AG, Wuppertal), on demand but not more than once a day. The patients were asked to take the study medication approximately 1 h before intended intercourse. The treatment lasted for 12 weeks.
Eligible patients were males aged 21 to 70-y-old who were seen at 39 centers in Belgium, France, Germany, The Netherlands, Poland, Republic of South Africa and the USA. The protocol for the study was approved at Institutional or ethical review boards for each center, details were explained to each patient who then signed an informed consent prior to starting the study. Of 601 who were randomized, 590 actually took placebo or drug. Men were required to be in a stable heterosexual relationship with ED for at least 6 months, de®ned as the inability to achieve or maintain penile erection suf®cient for satisfactory sexual performance. Men were excluded if they had diabetes mellitus, spinal cord injury, radical prostatectomy, signi®cant coronary heart disease, and history of hepatitis B andaor C. Patients with hypogonadal testosterone levels (`300 ngadl) and thyroid stimulating hormone (TSH) levels`0, 28 mUal were excluded. In addition, patients were speci®cally forbidden to take nitrate medications. No other ED treatments were permitted concurrently. Prior use of sildena®l was allowed but patients who had not responded to it were not included in this trial. For this phase II study, androgens, antiandrogens, anticoagulants (except low-dose aspirin), cimetidine, ketoconazole, or rifampicin were not allowed during the trial.
Ef®cacy outcome variables
The primary, prede®ned outcome variables were the scores of Questions 3 and 4 of the International Index of Erectile Function (IIEF). 27 Question 3 asks When you attempted sexual intercourse (vaginal penetration) how often were you able to penetrate your partner?' Question 4 asks`During sexual intercourse (vaginal penetration) how often were you able to maintain your erection after you have penetrated (entered) your partner?' These scores were graded on a scale of 1 ± 5, with 1 for never or almost never, and 5 for always or almost always with no intercourse noted as 0. In addition to these primary outcome variables, the various domains of sexual function were calculated from the responses to the IIEF. These domains were: Erectile Function (a summation of Questions 1 ± 5 plus Question 15), Intercourse Satisfaction (Q6, Q7 and Q8), Orgasmic Function (Q9 and Q10), Sexual Desire (Q11 and Q12) and Overall Satisfaction (Q13 and Q14).
In addition to these domains, patients answered the Fugl-Meyer Quality of Life Questionnaire which asks`How satisfactory are these different aspects of your life?' rating them from 1 (very dissatisfying) to 6 (very satisfying). 28 Patients were also asked a Global Assessment Question`Has the treatment you have been taking over the past 4 weeks improved your erections?' the answer to which was yes or no. In addition to these standardized questionnaires, patients were asked to keep a diary of the details of their sexual encounters. The de®nition of a successful attempt was that the following needed to occur: taking study medication (other than in the run-in period), attempting sexual intercourse, having an erection hard enough for penetration and lasting for enough time to complete sexual intercourse with ejaculation. The percentage of successful attempts was determined for each treatment group. In addition, the responder rate for each patient was determined by the same criteria and categorized as 25%, 25 ±`50%, 50 ± 75% and b 75%. Patients were followed regularly throughout the study but the outcome measures reported here are for the 12 week period.
Adverse events and safety
Patients were asked to record any adverse event during the course of the trial. The investigator noted whether these adverse events were mild, moderate or severe and, without knowledge of which treatment the patient was on, and taking into account the timing and other potential etiologies, categorized them as probably, possible or remotely drug-related. Vital signs were taken at every visit and blood and urine samples collected and analyzed. Patients were followed for a further 7 days after completing the 12 week treatment period to monitor for serious adverse effects.
Statistical analysis
The primary analysis of the primary ef®cacy variables was based on the intent-to-treat (ITT) population. Each of the two IIEF Questions 3 and 4 at week 12 (Last Observation Carried Forward, LOCF) were analyzed separately using analysis of covariance (ANCOVA) methods, based on the absolute scores, including terms for the baseline severity, center and treatment. Type III sums of squares were used in the model. The Bonferroni-Holm sequential rejective multiple test procedure was used to determine how many of the active groups were different from placebo. In order to demonstrate ef®cacy of vardena®l, a statistically signi®cant difference from placebo for at least one dose, for both questions, was required; the results from the Questions 3 and 4 had to also be consistent. The ®rst test of signi®-cance between a vardena®l dose group and placebo was at an a level of 0.0167. Assuming a standard deviation of 1.8 for Questions 3 and 4 and that both questions should indicate ef®cacy, it was concluded that approximately 108 patients per treatment group were required in order for the study to have 90% power to detect a response difference of 1 between the vardena®l dose group and placebo group for each of the two questions.
Changes from baseline were calculated for each individual and the arithmetic means of these changes were reported for each treatment group. In addition to the primary outcome variables, each secondary outcome variable was tested statistically for treatment effects and for differences between doses. An ANCOVA was used to determine treatment effects for the numerically scored IIEF domains and the Fugl-Meyer instrument. The responders in the Global Assessment Question (GAQ) were analyzed using a logistic regression model. This analysis was performed using PROC GENMOD in SAS, by specifying a binomial distribution and logit link function. The estimated proportions are reported from the logistic regression model which included factors for center and treatment. Logistic regression was also used for the sexual intercourse success rate obtained from the patient diary through use of the generalized estimating equations technique to account for repeated observations on each patient.
Results
Patient disposition
A total of 601 patients were randomized. Eleven patients did not take their medication leaving 590 patients eligible for the safety population: 152 in the placebo group, and 147, 141 and 150 in the 5, 10 and 20 mg vardena®l dose groups, respectively. Out of these 590, 10 patients did not have an ef®cacy evaluation at either baseline or post-baseline leaving 580 in the ITT population with 147 in the placebo group, and 146, 140 and 147 in the vardena®l 5, 10 and 20 mg dose groups, respectively. Out of these 580 patients, 74 patients exhibited a variety of protocol violations, leaving 506 in the Valid-forEf®cacy population (VfE) population. Of these, 124, 128, 123 and 131 were in the VfE for placebo, 5, 10 and 20 mg groups, respectively.
Patient demographics and characteristics
As seen in Table 1 , the characteristics of each group were very similar. Mean age for each group was approximately 52 y and the mean duration of ED approached 3 y. There was a similar mix of etiologies of ED among the groups with organic, psychogenic or mixed in approximately equal proportions. The distribution of baseline severity was also similar among groups with approximately equal numbers of mild, moderate or severe ED in each group. Severity was judged according to the rating of Cappelleri et al using the IIEF Erectile Function Domain. 29 Approximately half of the patients had taken sildena®l previously and these were equally distributed among the treatment groups. The mean number of tablets taken over the course of the 12 weeks were similar among the groups with 26 in the placebo, 29 in the 5 mg, 29 in the 10 mg and 31 in the 20 mg groups.
Ef®cacy
The primary ef®cacy variables on which the success of the trial was based were the responses to Q3 and Q4 in the ITT population. The baseline values, the ®nal values at 12 weeks and the mean change from baseline are reported in Table 2 with their respective standard deviations. The changes from baseline for each dose are also shown in Figure 1 . As can be seen, the initial baseline values were equivalent. There was no signi®cant change from baseline in the placebo group over the 12 week period while mean scores in all three doses of 5, 10 and 20 mg increased Table 3 . All three-dose regimens produced clear statistically signi®cant improvements in domain score. Thus the improvement in Erectile Function ranged from 5.7 to 9.0 and was related to dose, with the greatest bene®t for the 20 mg dose. Placebo groups did not increase from baseline. The change in Erectile Function for the 20 mg dose was statistically greater than that for the 5 mg dose (P`0.05) but while greater numerically than the 10 mg group, it was not statistically different. All the remaining domains had similar dose-related improvements over baseline and all were statistically signi®cantly greater than the changes for the placebo group. The Orgasmic Function showed the greatest increase for the 5 mg group. The biggest changes relative to the baseline scores were seen in Erectile Function while the smallest changes were seen in Sexual Desire.
The Fugl-Meyer has eight questions regarding various aspects of the quality of life of patients. All vardena®l treatment groups demonstrated a signi®-cant improvement in the mean score of the question relating to sex life satisfaction after 12 weeks of treatment. Changes in mean scores from baseline were 1.1, 1.5 and 1.7 for the 5, 10, and 20 mg doses, respectively. Treatment differences were signi®cantly different (P`0.001) from the placebo group, which had a change in mean score of only 0.5. No other question demonstrated a statistically signi®cant treatment effect. . Note that three patients in the placebo group and one in the 5 mg group did not answer all six questions of the IIEF domain and were therefore not included in this baseline severity analysis. 2.5 AE 1.5 3.5 AE 1.5 3.6 AE 1.5 3.8 AE 1.4 Change from baseline 0.5 AE 1.7 1.4 AE 1.7* 1.5 AE 1.6* 1.7 AE 1.6* *P`0.001 compared to change from baseline for placebo. 
Ef®cacy and tolerability of vardena®l H Porst et al
The GAQ, which asks if the quality of erections had improved while on treatment, demonstrated a marked increase in all vardena®l-treated groups (Figure 2 ). The estimated proportion from the logistic regression was 30% of placebo-treated patients who considered that their erections had improved over the previous 4 weeks. This compares to 66% for the 5 mg group, 76% for the 10 mg group and 80% for the 20 mg group. All vardena®l groups were signi®cantly greater than placebo (P`0.001). The 20 mg group was also signi®cantly greater than the 5 mg group (P`0.01).
Information from the patient diaries indicated that vardena®l was markedly effective in increasing the rate of success in completing intercourse. At baseline, the rates of successful intercourse (de®ned as attempting, penetrating and completing intercourse with ejaculation), were similar across all groups, ranging from 23.7 to 28.9%, as seen in Figure 3 . During treatment, the success rate for the placebo group increased slightly and had reached 39.5% over the last 4 weeks. All dosage groups of vardena®l recorded an improved rate of success and to a greater extent than the placebo group. For the 5 mg group, the success rate had increased to 71.1% during the last 4 weeks (Figure 3 ). Similar increases were seen for the 10 and 20 mg reaching 70.9 and 74.6%, respectively during the last 4 weeks. The proportion of successes were signi®cantly greater than for placebo (P`0.001). The reliability for each Figure 3 Percentage of successful intercourses for placebo and vardena®l-treated patients during the 4 week period at baseline and during the last 4 weeks of treatment. The data were derived from ITT patient diary data where a successful attempt was de®ned as attempting, penetrating and completing intercourse with ejaculation. (*Indicates signi®cantly greater than placebo, P`0.001.) Ef®cacy and tolerability of vardena®l H Porst et al patient was estimated from the proportion of patients achieving greater than a 75% success rate over a 4 week period. This was low at baseline, ranging from 12.3 to 14.1% of patients for all treatment groups (Table 4) . By 12 weeks, this had marginally increased to 27.0% of patients in the placebo group. In contrast, this had risen to between 57.4 and 65.3 % for the vardena®l treated groups by 12 weeks (Table 4) .
Safety and tolerability
The safety and tolerability pro®le of this trial is summarized in Table 5 . The treatment-emergent adverse events were mostly dose-dependent and showed a pro®le typical for PDE5 inhibitors with headache (7 ± 15%),¯ushing (10 ± 11%), dyspepsia (1 ± 7%) and rhinitis (3 ± 7%) as the most frequently encountered adverse events. No abnormal color vision perceptions such as dif®culties in discriminating blue ± green colors were reported which might be expected with PDE6 inhibition. In six patients, transiently increased brightness to light or mild haziness occurred both with vardena®l and placebo. In 12 patients, adverse events led to premature discontinuation: two with placebo, seven with 5 mg, two with 10 mg and one with 20 mg of vardena®l. A total of four serious adverse events occurred in the placebo arm, four in the 5 mg, one in the 10 mg and two in the 20 mg vardena®l arm but none of these serious adverse events were considered to be drug-related.
Discussion
The stated goal of this study was to demonstrate improvement in sexual function of ED patients when treated with at least one dose of vardena®l.
The predetermined primary endpoints of mean changes in Q3 and Q4 of the IIEF were both clearly statistically greater for vardena®l than placebo for all doses studied. Sexual function is, however, a complex physiological and psychological experience and success should be considered more than the physical act of achieving an erection and maintaining one for long enough to complete intercourse which Q3 and Q4 ascertain. The ®ve domains of the IIEF, derived from various combinations of the 15 questions, 27 are Erectile Function, Intercourse Satisfaction, Orgasmic Function, Sexual Desire and Overall Satisfaction. It is important to note that vardena®l treatment statistically improved all these domains when compared to placebo. The Sexual Desire domain had more borderline statistically signi®cant improvement which could be attributed more to the fact that, with increased erectile capacity and rate of success, there was a positive psychological effect rather than a centrally acting effect of a PDE5 inhibitor. The improvement in the other domains, however, was not only statistically signi®cantly better than placebo but could also be considered as clinically relevant. The Fugl-Meyer instrument con®rmed that vardena®l-treated patients had an increased satisfaction with their sex life. The GAQ asks a simple question if the erections had improved. The response was again in agreement with the IIEF individual Q3 and Q4 and domain responses in this study with as many as 80% responding that they had improved erections compared to 30% with placebo. The patient diaries also offer a more objective measure of success. Here the criteria of a success was having an erection, entering the partner and completing intercourse with an ejaculation. In the baseline period less than 30% of patients could achieve this criteria. After 12 weeks of on-demand dosing, the success rate had markedly increased to over 70% for all doses suggesting a The data were derived from ITT patient diaries, where available, with successful intercourse de®ned as attempting, penetrating and completing intercourse with ejaculation. Values for the 4 week baseline period are compared with the 8 ± 12 week period of treatment. clear treatment effect. Although it is important when evaluating a drug effect to look at the response of the group as a whole, it is also important to know the reliability of the response for each patient. Less than 15% of patients consistently achieved successful intercourse more than three quarters of the time at baseline. By 12 weeks, this had risen to 27% on placebo but, in contrast, 65.3% of patients on the highest dose had greater than three out of four successful attempts. These outcome measures indicated that patients had more than just a signi®cant increase in physical ability to achieve an erection but an actual increased ability to complete sexual intercourse with ejaculation. As this was the ®rst at-home use trial with the novel PDE5 inhibitor, vardena®l, the intention was to investigate appropriate doses in terms of ef®cacy and safety. ED patients who were less likely to respond to PDE5 inhibition such as diabetics, men with prostatectomies or known sildena®l nonresponders were excluded from enrollment. On the other hand, all levels of severity were included, even a number of mild cases. Comparisons with other studies should therefore be made cautiously since patient population, duration of treatment and treatment regimens are all likely to differ. Some studies with sildena®l, for example, used¯exible doses. 19, 20 In that situation, patients may move up a dose level if they are not responding or down a dose level if experiencing adverse events. This study used a ®xed-dose regimen. One similar study to this was included in the report of Goldstein et al 22 in which comparable ef®cacy outcomes were seen.
One of the notable features of this study was the adverse event rates. The number of patients in this study with over 140 in each treatment arm is likely to detect events with at least 1%. The most frequent adverse event of headache occurred in only 7% of patients at the lowest dose and for the highest dose was only 15%. The other most frequent adverse events were¯ushing, dyspepsia and rhinitis and all these are consistent with vardena®l's PDE5 inhibitory properties. Of note, no cardiovascular problems were found consistent with the selectivity pro®le of vardena®l on isolated PDE5, PDE1 and PDE3 enzymes. The same caveats for comparisons with other studies apply for adverse events as they do for ef®cacy, however, it is notable that the low rates seen in this study were in a ®xed-dose regimen rather than a¯exible dose. There were no blue colour vision complaints although a few cases of transient minor vision changes such as haziness and brightness were noted. This correlates with the selectivity pro®le from in vitro studies. 30 In conclusion, this large phase II study demonstrated that vardena®l was safe and well-tolerated with few patients reporting adverse events. All serious adverse events were considered unrelated to treatment and no signi®cant cardiovascular changes were detected. Importantly, it demonstrated that vardena®l was clearly ef®cacious in treating this population with mild to severe ED producing a high response rate with signi®cant improvement in the scores measuring sexual function and satisfaction. Further clinical trials are underway in larger controlled studies and also including populations that were excluded from this study to prove the ef®cacy and safety of vardena®l as a treatment of ED.
